BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38284882)

  • 1. HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation.
    Nishida H; Suzuki R; Nakajima K; Hayashi M; Morimoto C; Yamada T
    Cancer Res Commun; 2024 Feb; 4(2):349-364. PubMed ID: 38284882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1.
    Kumar P; Tripathi S; Pandey KN
    J Biol Chem; 2014 Mar; 289(10):6991-7002. PubMed ID: 24451378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSG gene expression is up-regulated by lysine acetylation involving histone and nonhistone proteins.
    Camolotto SA; Racca AC; Ridano ME; Genti-Raimondi S; Panzetta-Dutari GM
    PLoS One; 2013; 8(2):e55992. PubMed ID: 23418492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.
    Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D
    J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoregulation of mouse histone deacetylase 1 expression.
    Schuettengruber B; Simboeck E; Khier H; Seiser C
    Mol Cell Biol; 2003 Oct; 23(19):6993-7004. PubMed ID: 12972616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
    Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
    Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.
    Nishida H; Hayashi M; Morimoto C; Sakamoto M; Yamada T
    Blood Cancer J; 2018 Oct; 8(11):99. PubMed ID: 30348967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
    Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC
    Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase.
    Gan Y; Shen YH; Wang J; Wang X; Utama B; Wang J; Wang XL
    J Biol Chem; 2005 Apr; 280(16):16467-75. PubMed ID: 15722551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
    Gui CY; Ngo L; Xu WS; Richon VM; Marks PA
    Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1241-6. PubMed ID: 14734806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.
    Nebbioso A; Carafa V; Conte M; Tambaro FP; Abbondanza C; Martens J; Nees M; Benedetti R; Pallavicini I; Minucci S; Garcia-Manero G; Iovino F; Lania G; Ingenito C; Belsito Petrizzi V; Stunnenberg HG; Altucci L
    Clin Cancer Res; 2017 May; 23(10):2542-2555. PubMed ID: 27358484
    [No Abstract]   [Full Text] [Related]  

  • 15. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
    Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R
    Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
    Dai Y; Chen S; Wang L; Pei XY; Funk VL; Kramer LB; Dent P; Grant S
    J Biol Chem; 2011 Sep; 286(39):34036-50. PubMed ID: 21816815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
    Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
    BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.
    Tsai PF; Lin SJ; Weng PL; Tsai SC; Lin JH; Chou YC; Tsai CH
    J Virol; 2011 Mar; 85(5):2373-85. PubMed ID: 21159880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
    Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
    Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.